Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Silence Therapeutics Says Approach May Lead to Offer

Sept. 6 (Bloomberg) -- Silence Therapeutics Plc, whose shares have gained more than 30 percent since Sept. 2, said it has received an approach that may or may not lead to an offer.

The London-based company will make a further announcement in due course, it said in a statement today. The stock soared 4.76 pence, or 66 percent, the most since 1995, to close at 12 pence at 4:29 p.m. in London.

Silence Therapeutics in July extended a partnership with London-based AstraZeneca Plc by one year as the drugmaker seeks to develop medicines based on the U.K. biotechnology company’s technology to fight diseases by selectively switching off genes. Silence Therapeutics also is working with Quark Pharmaceuticals Inc. and Novartis AG. Silence Therapeutics last year merged with Intradigm Corp. of the U.S.

To contact the reporter responsible for this story: Angela Cullen at

To contact the editor responsible for this story: Kristen Hallam at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.